Health Condition 1: F202- Catatonic schizophrenia Health Condition 2: F201- Disorganized schizophrenia Health Condition 3: F200- Paranoid schizophrenia Health Condition 4: F205- Residual schizophrenia Health Condition 5: F251- Schizoaffective disorder, depressive type Health Condition 6: F209- Schizophrenia, unspecified Health Condition 7: F203- Undifferentiated schizophrenia
Conditions
Interventions
Intervention1: Medication and Yoga module (Yoga therapy group): A validated Yoga Module for Schizophrenia with duration approximately 60 minutes, adapted from the Integrated approach of yoga therapy f
Sponsors
Wellcome Trust DBT India Alliance
Eligibility
Inclusion criteria
Inclusion criteria: For Patients: 1. Diagnosis of schizophrenia (DSM V). 2. Clinical Global Impression â?? Severity (CGI-S)Score equal to or more than 3. 3. Stable medication for 6 weeks. 4. Right-handedness. 5. Written informed consent. For Healthy Controls: 1. Right-handedness. 2. Written informed consent.
Exclusion criteria
Exclusion criteria: For Patients: 1. Risk of harm to self or others. 2. Need for Electroconvulsive therapy. 3. Subjects who are already practicing/ recent practice of yoga/ meditation. 4. Recent history of high-grade fever/infection within the past 6 weeks. 5. Co-existing disease that can potentially influence immune system. 6. Treatment with medications known to affect immune system. 7. Significant neurological disorder including seizure disorder or recent head injury. 8. Family history of neurological disorder that may complicate diagnosis (for example Huntingtonâ??s chorea) 9. Co-morbid substance dependence in the past 6 months or substance abuse in the past 1month as per DSM - V, except nicotine. 10. Pregnancy or postpartum ( For Healthy Controls: 1. Diagnosis of a psychiatric disorder. 2. Family history of psychiatric disorder in any of the first-degree relatives 3. Recent history of high-grade fever/infection within the past 6 weeks 4. Co-existing disease including autoimmune/inflammatory conditions that can potentially influence immune system 5. Treatment with medications known to affect immune systems 6. Pregnancy or postpartum 7. Co-morbid substance dependence in the past 6 months or substance abuse in the past 1month as per DSM - V, except nicotine.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Plasma levels of Interleukin (IL)-1 beta, IL-6, IL-17, IL-10, Complement (C)3, C4 and C5Timepoint: Baseline and 3 month | — |
Secondary
| Measure | Time frame |
|---|---|
| Expression of Interleukin (IL)-1 beta, IL-6, IL-17, IL-10, Complement (C)3, C4 and C5 gene in peripheral blood mononuclear cells. DNA Methylation pattern of IL-1 beta, IL-6, IL-17, IL-10, C3, C4 and C5 gene in peripheral lymphocytes. Brief Cognitive Assessment Tool Social Occupational Functioning Scale.Timepoint: Baseline and 3 month | — |
Countries
India
Contacts
Public ContactDr Shivarama Varambally
National Institute of Mental Health and Neurosciences
Outcome results
None listed